ISAR-REACT 5 Substudy Confirms Prasugrel ACS Benefit Over Ticagrelor Irrespective of eGFR
A new substudy of the ISAR-REACT 5 trial has confirmed the surprise original finding – that prasugrel was more effective at reducing ischemic events in acute coronary syndrome (ACS) patients over the more potent antiplatelet drug ticagrelor – irrespective of estimated glomerular filtration rates (eGFR).